Product
Xgeva
3 clinical trials
4 indications
Indication
Bone metastasesIndication
Healthy Control ParticipantsIndication
Castration-resistant Prostate CancerIndication
Metastatic CancerClinical trial
A Randomised, Double-blind, Three-arm, Single-dose, Parallel Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity Profile of MB09 (Proposed Denosumab Biosimilar) and EU/US-sourced Xgeva® in Healthy Male VolunteersStatus: Completed, Estimated PCD: 2023-03-18
Clinical trial
A Multi-center, Randomized, Double-blind, Parallel Controlled Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of Recombinant Human Anti RANKL Monoclonal Antibody Injection (MW032) and Denosumab (Xgeva®) in Subjects With Bone Metastases From Solid TumorsStatus: Completed, Estimated PCD: 2021-04-29
Clinical trial
A Phase II Study of Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.Status: Terminated, Estimated PCD: 2019-01-12